Tarsons Products Ltd

- Current debt levels stand at around INR 260-270 crores, with an average interest rate of about 8.25-8.3%. - The company is both taking additional debt and repaying existing debt, keeping net debt stable. - Peak debt going forward is forecasted not to exceed INR 300 crores due to ongoing repayments. - No explicit mention of any new equity fundraising in the recent call. - Focus is currently on stabilizing post recent acquisition (Nerbe) and completing large capex projects rather than raising new funds. - No indicated plans for major debt or equity fundraising announced during the call.

- Tarsons is executing a large capex program totaling around INR 550-600 crores. - Approximately INR 525 crores have already been spent; remaining capex to be incurred over the next 6 to 12 months. - Major focus is on the Panchla facility with capex around INR 300 crores aimed at manufacturing and growth. - The Panchla plant expansion is largely centered on new products (>70%), with <30% capacity addition for existing products. - Additional capex of around INR 300 crores is directed towards existing plants like Amta, Jangalpur, and Dhulagarh. - A sizable logistics and storage facility is planned but the INR 300 crores cited largely pertains to manufacturing, not logistics. - Machinery installation at Panchla is progressing but delayed due to transit damage; commissioning expected in second half of FY25. - The new capacities are targeted to start contributing to revenue post-installation, with 6-8 months anticipated for full machine installations.

- The plastic labware industry faced a 30-35% revenue decline post-COVID peak (FY '22), but Tarsons limited decline to 6-7% due to strong market share. - Signs of industry recovery are visible with increased order inquiries in domestic and international markets. - Tarsons is heavily participating in large RFQs and global tenders, aiming to win more international business in H2 FY '25 and beyond. - New Panchla facility (INR300 crores capex) expected to start contributing from H2 FY '25, with full machine installation over next 6-10 months. - Global market will play a big role for Panchla’s capacity utilization; revenues expected to grow as new capacities come online. - Nerbe acquisition (EUR 10 million company) offers significant synergy potential; management aims for multi-fold growth but exact figures and timelines remain uncertain. - Domestic diagnostic segment has stabilized after COVID-related demand spike normalization. - Overall, long-term sector growth expected, with investment focused on expanding manufacturing and international presence.

- The company expects revenue growth driven by new product introductions and international market expansion, particularly leveraging the Nerbe acquisition and the large Panchla facility. - Panchla plant's capacity installation is expected over the next 6-10 months, with meaningful top-line contribution beginning thereafter, enhancing operating leverage. - Management anticipates stabilization and recovery in domestic diagnostic sector demand post-COVID. - While consolidated EBITDA margins were impacted in Q1 FY25 by several factors (insurance claim provision, product mix, employee expenses, and lower-margin trading entity Nerbe Plus), the stand-alone business aims to maintain mid-40% EBITDA margins as scale increases. - Nerbe margins (~10%-12% EBITDA) are expected to remain steady, with incremental value-addition potentially improving profitability. - Peak debt is forecasted to stay below INR 300 crores, supporting financial stability. - Overall, management is cautiously optimistic but notes macro uncertainties and competition as variables impacting future profit growth.

- Tarsons Products Limited does not disclose specific order book or pending order details at the company level. - Orders are only reflected in sales once executed, hence no guidance or numbers on order book are provided. - The company maintains confidentiality on order details like type, value, or customer identity. - Santosh Agarwal stated the current debt is around INR 260-270 crores with ongoing repayments, but this does not provide direct insights on order book. - Aryan Sehgal emphasized no disclosure of order specifics, even when orders are received. - The company focuses on managing orders daily but only reports revenues post order fulfillment. - Overall, no broad or ballpark figures on current or expected order books were shared publicly.